KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBITDA: 2018-2024

Historic EBITDA for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $8.7 million.

  • Castle Biosciences' EBITDA fell 233.96% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 3265.41%. This contributed to the annual value of $8.7 million for FY2024, which is 112.75% up from last year.
  • Castle Biosciences' EBITDA amounted to $8.7 million in FY2024, which was up 112.75% from -$68.0 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' EBITDA registered a high of $8.7 million during FY2024, and its lowest value of -$72.9 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$68.0 million (2023), whereas its average is -$44.1 million.
  • Per our database at Business Quant, Castle Biosciences' EBITDA tumbled by 294.88% in 2020 and then spiked by 112.75% in 2024.
  • Castle Biosciences' EBITDA (Yearly) stood at -$10.3 million in 2020, then crashed by 204.28% to -$31.3 million in 2021, then plummeted by 132.82% to -$72.9 million in 2022, then grew by 6.70% to -$68.0 million in 2023, then surged by 112.75% to $8.7 million in 2024.